XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।
G
G

Galapagos


समाचार

Compass Group, Pandora, SSP Group

EUROPE RESEARCH ROUNDUP-Compass Group, Pandora, SSP Group Nov 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Compass Group, Pandora and SSP Group, on Thursday. HIGHLIGHTS * Compass Group CPG.L : Jefferies raises target price to 3,000p from 2,500p * Just Eat Takeaway.Com JETJ.L : JP Morgan raises target price to 1,415p from 1,396p * Marks and Spencer Group MKS.L : JP Morgan raises target price to 440p from 425p * Pandora PNDORA.C
A
B
C
C
E
F
F
G
G
I
K
M
P
P
S
S
S
S
S
Z
A

Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary

Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary Galapagos NV GLPG.AS reported a quarterly adjusted loss of 77 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 39 cents. The mean expectation of two analysts for the quarter was for a loss of 49 cents per share.
G

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 30 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. VIVENDI VIV.PA : Paris-based investment fund CIAM said on Tuesday it would appeal to France's financial watchdog AMF to ensure shareholder rights are respected in Vivendi's plan to split up, urging a public offer be launched for Vivendi shares.
E
G
V
F
N
U

Galapagos NV <GLPG.OQ> expected to post a loss of 27 cents a share - Earnings Preview

Galapagos NV expected to post a loss of 27 cents a share - Earnings Preview Galapagos NV GLPG.OQ , GLPG.O is expected to show a fall in quarterly revenue when it reports results on October 30 for the period ending January 1 0001 The Malines (mechelen) Antwerpen-based company is expected to report a 41.8% decrease in revenue to $69.796 million from $120.03 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
G

Basler AG, Greatland Gold, Sandvik AB

EUROPE RESEARCH ROUNDUP-Basler AG, Greatland Gold, Sandvik AB Oct 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Basler AG, Greatland Gold and Sandvik AB, on Tuesday. HIGHLIGHTS * Autoneum Holding AG AUTON.S : UBS raises PT to CHF 170 from CHF 160 * Azelis NV AZE.BR : HSBC raises to buy from hold * Basler AG BSLG.DE : Jefferies cuts to hold from buy * Greatland Gold Plc GGPL.L : Berenberg cuts to hold from buy * Sandvik AB SAND
A
B
E
F
G
I
I
N
P
R
S
S
S
T
R

U.S. Galapagos, Marsh & Mclennan, Travelers

U.S. RESEARCH ROUNDUP-Galapagos, Marsh & Mclennan, Travelers Oct 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Galapagos, Marsh & Mclennan and Travelers, on Tuesday. HIGHLIGHTS * Contineum Therapeutics Inc CTNM.O : Baird initiates coverage with outperform rating * Galapagos NV GLPG.O : JP Morgan cuts target price to $32 from $37 * Marsh & Mclennan MMC.N : KBW raises target price to $212 from $209 * Travelers TRV.
A
C
E
E
G
M
T
W
Z
A
F
T
L
P
U
W
P
S

Galapagos jumps after appointing EcoR1's Nodelman to its board

BUZZ-Galapagos jumps after appointing EcoR1's Nodelman to its board ** Shares in pharmaceutical company Galapagos GLPG.AS rise 4.3% after it appoints Oleg Nodelman, founder and portfolio manager of EcoR1 Capital, to its board of directors ** EcoR1 in August reported a 9.9% stake in Galapagos and said it planned to communicate with the management and the board about topics relating to co's performance and board composition ** "(Nodelman) will bring his track record in business development and cap
G

Galapagos Receives Transparency Notification From Ecor1 Capital

BRIEF-Galapagos Receives Transparency Notification From Ecor1 Capital Sept 16 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATION FROM ECOR1 CAPITAL Source text for Eikon: ID:nGNX1Q9lfM Further company coverage: GLPG.AS ( Reuters.Briefs@thomsonreuters.com )
G

Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19

BRIEF-Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19 Aug 23 (Reuters) - Galapagos NV GLPG.AS : ECOR1 CAPITAL LLC REPORTS 9.9% STAKE IN GALAPAGOS NV AS OF AUG 19 - SEC FILING ECOR1 CAPITAL LLC SAYS BELIEVES GALAPAGOS NV'S SECURITIES ARE DEEPLY "UNDERVALUED" ECOR1 CAPITAL LLC - INTENDS TO COMMUNICATE WITH GALAPAGOS’ MANAGEMENT, BOARD
G

U.S. STOCKS Workday, Roku, Dexcom

BUZZ-U.S. STOCKS ON THE MOVE-Workday, Roku, Dexcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's stock indexes jumped on Friday, with the benchmark S&P 500 index nearing a record high, after U.S. Federal Reserve Chair Jerome Powell said "the time has come" to reduce interest rates.
G
I
Q
L
R
U
U

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to open higher on Friday ahead of a speech from Federal Reserve Chair Jerome Powell that investors expect will offer hints on the pace of rate cuts in the world's biggest economy.
G
Q
R
U
E

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Friday with investors awaiting Federal Reserve Chair Jerome Powell's comments at the Jackson Hole Economic Symposium for clues on interest-rate cuts in the world's biggest economy.
G
R
U
E

Galapagos rises on FDA clearance for phase 1/2 1 study

BUZZ-Galapagos rises on FDA clearance for phase 1/2 ATALANTA-1 study ** Shares in Galapagos GLPG.AS rise 2.7%, paring earlier gains of as much as 4%, after the Belgian biotech company obtained FDA clearance to initiate its ATALANTA-1 study with GLPG5101 in the U.S. ** "We see the FDA clearance as an important milestone for Galapagos' GLPG5101 program," says KBC Securities, adding the company will now be able to start treating patients in the U.S.
G
K

Galapagos: FDA Clears IND Application For Phase 1/2 1 Study

BRIEF-Galapagos: FDA Clears IND Application For Phase 1/2 ATALANTA-1 Study Aug 23 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 ATALANTA-1 STUDY OF CD19 CAR-T, GLPG5101, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA Source text for Eikon: ID:nGNX1gGlDF Further company coverage: GLPG.AS (Gdansk N
G

Ashtead Group, Beazley, Entain

EUROPE RESEARCH ROUNDUP-Ashtead Group, Beazley, Entain Aug 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Group, Beazley and Entain, on Friday. HIGHLIGHTS * Ashtead Group Plc AHT.L : KeyBanc initiates coverage with sector weight rating * Beazley Plc BEZG.L : Berenberg raises target price to 950p from 880p * Entain Plc ENT.L : Deutsche Bank cuts target price to 958p from 1,089p * Rheinmetall AG RHMG.DE : Morgan Stanley up
A
A
A
A
B
B
B
C
C
D
D
E
G
G
H
H
H
I
K
O
B



स्थितियाँ

लोकप्रिय परिसंपत्तियाँ

अस्वीकरण: XM Group के सत्व केवल निष्पादन वाली सेवा और हमारी ऑनलाइन व्यापार सुविधा में पहुँच प्रदान करते हैं, ताकि व्यक्ति वेबसाइट पर या उसके जरिए उपलब्ध सामग्री को देख सके और/या उसका उपयोग कर सके। इसका प्रयोजन इसे बदलना या विस्तार देना नहीं है, न ही वह इसे बदलता या विस्तार देता है। इस तरह की पहुँच हमेशा ही निम्नलिखित के अधीन रहेगी: (1) नियम और शर्तें; (2) जोखिम चेतावनियाँ; और (3) पूर्ण अस्वीकरण। इसलिए ऐसी जानकारी सामान्य सूचना से अधिक कुछ भी नहीं है। विशेष रूप से, कृपया इससे अवगत रहें कि हमारी ऑनलाइन व्यापार सुविधा की सामग्रियाँ न तो किसी चीज का अनुरोध करती हैं, न ही वित्तीय बाजारों में प्रवेश करने की पेशकश ही करती हैं। किसी भी वित्तीय बाजार में व्यापार करने के साथ आपकी पूँजी को उल्लेखनीय जोखिम है।

हमारी ऑनलाइन व्यापार सुविधा में प्रकाशित सभी सामग्रियाँ शैक्षणिक/सूचनात्मक प्रयोजनों मात्र के लिए हैं, और इनमें वित्तीय, निवेश टैक्स या व्यापार सलाह और सुझाव नहीं हैं - न ही ऐसा समझना चाहिए कि इनमें ये सब हैं; न ही इनमें हमारी व्यापार कीमतों का अभिलेख है; न ही इनमें किसी वित्तीय उपकरण में लेन-देन करने का निमंत्रण या अनुरोध है; न ही ये आपको अवांछित वित्तयी प्रोमोशन पेश करती हैं।

इस वेबसाइट में मौजूद कोई भी तृतीय पक्षीय सामग्री, तथा XM द्वारा तैयार की गई सामग्रियाँ, जैसे: अभिप्राय, समाचार, अनुसंधान, विश्लेषण, कीमतें और अन्य सूचनाएँ या तृतीय पक्षों की साइटों के लिंक, "जैसा-है-वैसा" के आधार पर बाजार के बारे में सामान्य टिप्पणी के रूप में उपलब्ध कराई गई हैं, और वे निवेश हेतु सलाह नहीं हैं। जिस हद तक कीसी सामग्री को निवेश अनुसंधान मान लिया जाता है, उस हद तक आपको ध्यान में रखना होगा और इसे स्वीकार करना होगा कि वह सामग्री इस उद्देश्य से और निवेश अनुसंधान की स्वतंत्रता को बढ़ावा देने के लिए कानूनी आवश्यकताओं के मुताबिक, तैयार नहीं की गई है, और इसलिए उसे प्रासंगिक कानूनों और विनियमों के तहत विपणन संप्रेषण माना जाएगा। कृपया सुनिश्चित करें कि आपने गैर-आश्रित निवेश के बारे में हमारी सूचना को पढ़ और समझ लिया है। पीछे दी गई जानकारी के बारे में अनुसंधान और जोखिम चेतावनी यहाँ उपलब्ध है।

जोखिम की चेतावनी: आपकी पूँजी जोखिम में है। लीवरेज वाले उत्पाद सबके उपयुक्त नहीं होते हैं। कृपया हमारे जोखिम खुलासे पर विचार करें।